Search

Displaying results 6111 - 6120 of 10000 in total
  1. Drug

    Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB16720
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  2. Drug

    Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB16722
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  3. Drug

    Influenza A virus A/Brisbane/02/2018 IVR-190 (H1N1) antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB15500
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  4. Drug

    Influenza B virus B/Iowa/06/2017 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15508
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  5. Drug

    Influenza A virus A/Brisbane/02/2018 IVR-190 (H1N1) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB15519
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  6. Drug

    Influenza B virus B/Singapore/INFTT-16-0610/2016 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15564
    Approved

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  7. Drug

    Pipendoxifene

    go.drugbank.com/drugs/DB05414
    Investigational

    ER modulator, ERA-923(Pipendoxifene) is a estrogen receptor modulator being evaluated for the treatment of breast cancer. … Pipendoxifene is a new 2-phenyl indole selective estrogen receptor modulators (SERM )that exhibits an excellent preclinical pharmacological profile and was selected for further development as a treatment

  8. Drug

    Prenalterol

    go.drugbank.com/drugs/DB13777
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Ebselen

    go.drugbank.com/drugs/DB12610
    Investigational

    Ebselen has been investigated for the treatment and basic science of Meniere's Disease, Type 2 Diabetes Mellitus, and Type 1 Diabetes Mellitus.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Talacotuzumab

    go.drugbank.com/drugs/DB14796
    Investigational

    It is under investigation in clinical trial NCT01632852 (A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission). … Talacotuzumab is an IgG1 monoclonal antibody directed toward the IL3 receptor α–subunit, also known as CD123.